CRSP icon

CRISPR Therapeutics

415 hedge funds and large institutions have $3.07B invested in CRISPR Therapeutics in 2023 Q2 according to their latest regulatory filings, with 65 funds opening new positions, 94 increasing their positions, 136 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
415
Holders Change
+36
Holders Change %
+9.5%
% of All Funds
6.55%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
65
Increased
94
Reduced
136
Closed
26
Calls
$142M
Puts
$112M
Net Calls
+$30M
Net Calls Change
+$22.1M
Name Holding Trade Value Shares
Change
Shares
Change %
GC
351
Gould Capital
Washington
$6.18K
BFEC
352
Benjamin F. Edwards & Company
Missouri
$6K
FWM
353
Focused Wealth Management
New York
$5.61K
WWM
354
Wolff Wiese Magana
California
$5.61K
OIA
355
Optimum Investment Advisors
Illinois
$5.61K
RAM
356
Riggs Asset Management
Pennsylvania
$5.61K +$5.61K +100 New
PIAS
357
PCA Investment Advisory Services
Ohio
$5.61K +$5.61K +100 New
VF
358
VitalStone Financial
Texas
$5K -$2.44K -63 -33%
GIA
359
GHP Investment Advisors
Colorado
$4.97K
GM
360
Gilfoyle Management
Connecticut
$4.84K +$4.84K +100 New
PB
361
Pinnacle Bancorp
Nebraska
$4.83K
WPA
362
West Paces Advisors
Georgia
$4.77K
PK
363
Pflug Koory
Nebraska
$4.72K
PCFFS
364
Pacific Center for Financial Services
California
$4.55K
BWM
365
Baystate Wealth Management
Massachusetts
$3.43K
LF
366
Lee Financial
Texas
$3.37K
BFPW
367
BOK Financial Private Wealth
Colorado
$3.37K
RA
368
Rise Advisors
New York
$3.37K
DAC
369
Dividend Assets Capital
South Carolina
$3K
ADL
370
Asset Dedication LLC
California
$3K +$1.23K +23 +70%
BCM
371
Bourgeon Capital Management
Connecticut
$2.81K -$112K -2,000 -98%
First Manhattan
372
First Manhattan
New York
$2.81K
WBC
373
West Branch Capital
Massachusetts
$2.81K
LFA
374
Level Financial Advisors
New York
$2.64K
TFP
375
Tilia Fiduciary Partners
North Carolina
$2.36K